Cleo Diagnostics (ASX:COV) started the technology transfer activities to develop its blood test designed for early detection of ovarian cancer, according to a Tuesday filing with the Australian bourse.
The technology transfer includes the transfer of its in-house development activities to a manufacturer to support commercial production, the filing said.
Accordingly, the company has partnered with US-based R&D Systems, a unit of Bio-Techne Group, to handle pre-production kit assembly and testing, the filing added.
After successful testing, a selected contract manufacturing organization (CMO) will expand production and complete verification and validation to produce in-vitro diagnostic kits for clinical use, the company said.
Final negotiations with US Food and Drug Administration-approved CMOs are underway, with the selection based on manufacturing capacity and regulatory compliance, the company added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。